文献速递临床免疫质量管理与危急值

全自动化学发光酶免疫分析法诊断阿尔茨海默病的性能评估

Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis.
PubMed 文献 · Clin Chim Acta · 2019-03-13

该研究评估了全自动化学发光酶免疫分析(LUMIPULSE)检测脑脊液Aβ42和t-Tau对阿尔茨海默病(AD)的诊断性能,并与传统手工ELISA比较。纳入临床诊断AD患者42例和非AD患者38例,随访确认诊断。LUMIPULSE检测的Aβ42在AD中降低、t-Tau在AD中升高,两者区分AD与非AD的准确性良好,且与手工ELISA高度相关。

要点

  • LUMIPULSE检测脑脊液Aβ42和t-Tau可有效区分AD与非AD患者。
  • LUMIPULSE t-Tau的AUC达0.94,敏感度0.87、特异度0.93。
  • LUMIPULSE与手工ELISA检测结果高度相关(Aβ42 r=0.87,t-Tau r=0.92)。

核心结论

  • LUMIPULSE全自动化学发光酶免疫分析可提高AD诊断的临床准确性,促进脑脊液生物标志物标准化值的应用,且与经典手工检测方法相关性良好。

研究设计与样本

  • 研究纳入临床诊断为AD的患者42例和非AD患者38例,临床诊断经随访确认,比较全自动化学发光酶免疫分析(LUMIPULSE)与经典手工酶联免疫吸附试验(ELISA)的诊断性能。

主要发现

  • LUMIPULSE检测的Aβ42在AD患者中降低(969.4 ± 329.6 pg/mL vs. 1625.9 ± 745.9 pg/mL,p <0.001)。
  • LUMIPULSE检测的t-Tau在AD患者中升高(768.2 ± 281.0 pg/mL vs. 337.5 ± 159.1 pg/mL,p < 0.001)。
  • LUMIPULSE Aβ42区分AD与非AD的AUC为0.78,特异度0.74,敏感度0.76。
  • LUMIPULSE t-Tau区分AD与非AD的AUC为0.94,特异度0.93,敏感度0.87。
  • LUMIPULSE与手工ELISA高度相关:Aβ42 r = 0.87(p < 0.001),t-Tau r = 0.92(p < 0.001)。

临床怎么用

  • 在临床诊断AD时,可采用全自动LUMIPULSE检测脑脊液Aβ42和t-Tau,其与手工ELISA结果高度相关且有助于标准化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The variability of Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers (Aβ42, t-Tau and p-Tau) undermines their full-fledged introduction into routine diagnostics and clinical trials. The introduction of automatic systems can improve the diagnostic performance promoting standardization and reducing the impact of preanalytical and analytical factors. Here we assessed the diagnostic performance of a fully automated chemiluminescent enzyme assay (LUMIPULSE) and compared it with that obtained by using the classical manual enzyme-linked immunosorbent assays (ELISAs). Patients were clinically diagnosed as AD (n = 42) and non-AD (n = 38). Clinical diagnosis was confirmed at follow-up. LUMIPULSE Aβ42 was reduced in AD (969.4 ± 329.6 pg/mL vs. 1625.9 ± 745.9 pg/mL, p <0.001), whereas LUMIPULSE t-Tau was increased in AD (768.2 ± 281.0 pg/mL vs. 337.5 ± 159.1 pg/mL, p < 0.001) compared to non-AD patients. Both LUMIPULSE Aβ42 (AUC = 0.78, spec. = 0.74, sens. = 0.76) and t-Tau (AUC = 0.94, spec. = 0.93, sens. = 0.87) showed good accuracy in distinguish AD from non-AD and a high correlation with the manual ELISAs (r = 0.87, p < 0.001 and r = 0.92, p < 0.001, respectively). LUMIPULSE improves clinical accuracy in AD diagnosis, promoting the use of standardized values for CSF biomarkers with a good correlation with classical manual assays.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Paciotti S, Sepe FN, Eusebi P, et al. Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis. Clin Chim Acta. 2019. PMID: 30878539. doi:10.1016/j.cca.2019.03.1612

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。